Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF-POLARIS: NNC0487-0111 versus placebo in obesity-related HFpEF/HFmrEF
MOH_2026-02-23_015682Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jan 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in heart failure with preserved ejection fraction (HFpEF), heart failure with mid-range ejection fraction (HFmrEF) and obesity comparing NNC0487-0111 with Placebo (2 arms). Started Jan 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)obesity
Beyond the preview
Go deeper on MOH_2026-02-23_015682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-23_015682.